Barclays PLC restated their equal weight rating on shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) in a research note published on Thursday morning. The firm currently has a $34.00 target price on the specialty pharmaceutical company’s stock.

VRX has been the subject of several other reports. TD Securities restated a hold rating and issued a $38.00 target price on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Mizuho reiterated an underperform rating on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Wells Fargo & Co. reiterated a sell rating and set a $19.50 price target on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Rodman & Renshaw reiterated a buy rating and set a $90.00 price target on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Finally, Morgan Stanley lowered their price target on Valeant Pharmaceuticals International from $42.00 to $25.00 and set an overweight rating for the company in a report on Thursday, November 10th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $39.97.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Valeant Pharmaceuticals International (NYSE:VRX) opened at 17.55 on Thursday. The stock has a 50 day moving average of $22.04 and a 200 day moving average of $25.21. The company’s market cap is $6.10 billion. Valeant Pharmaceuticals International has a 52 week low of $13.77 and a 52 week high of $119.87.

Valeant Pharmaceuticals International (NYSE:VRX) last posted its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.78 by $0.23. Valeant Pharmaceuticals International had a negative net margin of 22.17% and a positive return on equity of 43.81%. The company earned $2.48 billion during the quarter, compared to analysts’ expectations of $2.49 billion. During the same quarter last year, the firm earned $2.74 EPS. Valeant Pharmaceuticals International’s revenue for the quarter was down 11.0% on a year-over-year basis. Equities research analysts predict that Valeant Pharmaceuticals International will post $5.63 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the stock. Riggs Asset Managment Co. Inc. raised its stake in Valeant Pharmaceuticals International by 1.4% in the second quarter. Riggs Asset Managment Co. Inc. now owns 14,044 shares of the specialty pharmaceutical company’s stock worth $283,000 after buying an additional 200 shares during the last quarter. Capstone Asset Management Co. raised its stake in Valeant Pharmaceuticals International by 1.4% in the third quarter. Capstone Asset Management Co. now owns 26,408 shares of the specialty pharmaceutical company’s stock worth $648,000 after buying an additional 360 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock worth $129,000 after buying an additional 402 shares during the last quarter. Allen Investment Management LLC raised its stake in Valeant Pharmaceuticals International by 4.1% in the first quarter. Allen Investment Management LLC now owns 12,411 shares of the specialty pharmaceutical company’s stock worth $326,000 after buying an additional 493 shares during the last quarter. Finally, Breton Hill Capital Ltd. raised its stake in Valeant Pharmaceuticals International by 3.7% in the second quarter. Breton Hill Capital Ltd. now owns 17,379 shares of the specialty pharmaceutical company’s stock worth $350,000 after buying an additional 627 shares during the last quarter. Institutional investors own 65.50% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.